Perry Shen, MD, FACS, and Clancy Clark, MD, from Wake Forest Baptist Health Comprehensive Cancer Center, discuss advances in the management of hepatic and pancreatic malignancies.

The oncology we all learned over the past three decades will soon be a thing of the past, making way for therapy decisions based on what molecular switches should be turned on and off, and of equal importance, in what sequence.

Recently reported data demonstrate that the presence of a specific mutation in PDGFRA predicts for the lack of activity for the imatinib in patients with gastrointestinal stromal tumors.